Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
Original Article from The New England Journal of Medicine - Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 5, 2018
|
| In: |
The New England journal of medicine
Year: 2018, Volume: 379, Issue: 1, Pages: 11-21 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1716153 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1056/NEJMoa1716153 Verlag, Volltext: https://www.nejm.org/doi/10.1056/NEJMoa1716153 |
| Author Notes: | D. Adams, A. Gonzalez-Duarte, W.D. O’Riordan, C.-C. Yang, M. Ueda, A.V. Kristen, I. Tournev, H.H. Schmidt, T. Coelho, J.L. Berk, K.-P. Lin, G. Vita, S. Attarian, V. Planté-Bordeneuve, M.M. Mezei, J.M. Campistol, J. Buades, T.H. Brannagan III, B.J. Kim, J. Oh, Y. Parman, Y. Sekijima, P.N. Hawkins, S.D. Solomon, M. Polydefkis, P.J. Dyck, P.J. Gandhi, S. Goyal, J. Chen, A.L. Strahs, S.V. Nochur, M.T. Sweetser, P.P. Garg, A.K. Vaishnaw, J.A. Gollob, and O.B. Suhr |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1663508445 | ||
| 003 | DE-627 | ||
| 005 | 20220816140735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190423s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1716153 |2 doi | |
| 035 | |a (DE-627)1663508445 | ||
| 035 | |a (DE-599)KXP1663508445 | ||
| 035 | |a (OCoLC)1341211623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Adams, David B. |d 1950- |e VerfasserIn |0 (DE-588)1132276829 |0 (DE-627)887689612 |0 (DE-576)48877022X |4 aut | |
| 245 | 1 | 0 | |a Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis |c D. Adams, A. Gonzalez-Duarte, W.D. O’Riordan, C.-C. Yang, M. Ueda, A.V. Kristen, I. Tournev, H.H. Schmidt, T. Coelho, J.L. Berk, K.-P. Lin, G. Vita, S. Attarian, V. Planté-Bordeneuve, M.M. Mezei, J.M. Campistol, J. Buades, T.H. Brannagan III, B.J. Kim, J. Oh, Y. Parman, Y. Sekijima, P.N. Hawkins, S.D. Solomon, M. Polydefkis, P.J. Dyck, P.J. Gandhi, S. Goyal, J. Chen, A.L. Strahs, S.V. Nochur, M.T. Sweetser, P.P. Garg, A.K. Vaishnaw, J.A. Gollob, and O.B. Suhr |
| 264 | 1 | |c July 5, 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.05.2019 | ||
| 520 | |a Original Article from The New England Journal of Medicine - Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis | ||
| 700 | 1 | |a Kristen, Arnt |d 1974- |e VerfasserIn |0 (DE-588)123480965 |0 (DE-627)706314530 |0 (DE-576)293726876 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 379(2018), 1, Seite 11-21 |h Online-Ressource |w (DE-627)266889484 |w (DE-600)1468837-2 |w (DE-576)075962454 |x 1533-4406 |7 nnas |a Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis |
| 773 | 1 | 8 | |g volume:379 |g year:2018 |g number:1 |g pages:11-21 |g extent:11 |a Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis |
| 856 | 4 | 0 | |u https://doi.org/10.1056/NEJMoa1716153 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nejm.org/doi/10.1056/NEJMoa1716153 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190423 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 123480965 |a Kristen, Arnt |m 123480965:Kristen, Arnt |d 910000 |d 910100 |e 910000PK123480965 |e 910100PK123480965 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 999 | |a KXP-PPN1663508445 |e 3453020340 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1663508445","note":["Gesehen am 07.05.2019"],"relHost":[{"pubHistory":["198.1928 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 04.08.25"],"recId":"266889484","part":{"issue":"1","volume":"379","extent":"11","year":"2018","pages":"11-21","text":"379(2018), 1, Seite 11-21"},"id":{"eki":["266889484"],"zdb":["1468837-2"],"issn":["1533-4406"]},"titleAlt":[{"title":"NEJM"}],"corporate":[{"display":"Massachusetts Medical Society","roleDisplay":"Herausgebendes Organ","role":"isb"}],"name":{"displayForm":["Massachusetts Medical Society"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"1928","publisherPlace":"Waltham, Mass. ; Boston, Mass.","dateIssuedDisp":"1928-","publisher":"MMS ; MMS"}],"language":["eng"],"disp":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosisThe New England journal of medicine","title":[{"subtitle":"NEJM","title_sort":"New England journal of medicine","title":"The New England journal of medicine"}]}],"name":{"displayForm":["D. Adams, A. Gonzalez-Duarte, W.D. O’Riordan, C.-C. Yang, M. Ueda, A.V. Kristen, I. Tournev, H.H. Schmidt, T. Coelho, J.L. Berk, K.-P. Lin, G. Vita, S. Attarian, V. Planté-Bordeneuve, M.M. Mezei, J.M. Campistol, J. Buades, T.H. Brannagan III, B.J. Kim, J. Oh, Y. Parman, Y. Sekijima, P.N. Hawkins, S.D. Solomon, M. Polydefkis, P.J. Dyck, P.J. Gandhi, S. Goyal, J. Chen, A.L. Strahs, S.V. Nochur, M.T. Sweetser, P.P. Garg, A.K. Vaishnaw, J.A. Gollob, and O.B. Suhr"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"July 5, 2018"}],"id":{"doi":["10.1056/NEJMoa1716153"],"eki":["1663508445"]},"physDesc":[{"extent":"11 S."}],"language":["eng"],"person":[{"display":"Adams, David B.","role":"aut","roleDisplay":"VerfasserIn","given":"David B.","family":"Adams"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Arnt","display":"Kristen, Arnt","family":"Kristen"}],"title":[{"title_sort":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis"}]} | ||
| SRT | |a ADAMSDAVIDPATISIRANA5201 | ||